Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the easy-accordion-free domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u144920493/domains/currencyveda.com/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u144920493/domains/currencyveda.com/public_html/wp-includes/functions.php on line 6114
IPO Listing: Kronox Lab Sciences Share Price Debuts at ₹165, a 21% Premium to Issue Price - CurrencyVeda
TOP NEWS

IPO Listing: Kronox Lab Sciences Share Price Debuts at ₹165, a 21% Premium to Issue Price

IPO

June 10, 2024

New Delhi, India

IPO Watch

Kronox Lab Sciences made a strong debut on the stock exchanges, listing at ₹164.95 on the NSE and ₹165 on the BSE, both reflecting a 21% premium to the issue price of ₹136. This successful listing underscores investor confidence and robust demand, as evidenced by the IPO’s oversubscription.

IPO Subscription Details

The initial public offering (IPO) of Kronox Lab Sciences, amounting to ₹130.15 crore, was open for subscription from June 3-5 with a price band of ₹129-136. The IPO was oversubscribed by 117.25 times, receiving bids for 98.54 crore shares against the 95.70 lakh shares on offer. The subscription breakdown is as follows:

  • Non-Institutional Investors (NII): Subscribed 301.92 times
  • Qualified Institutional Buyers (QIB): Subscribed 89.03 times
  • Retail Investors: Subscribed 52.24 times

The issue was entirely an offer for sale (OFS) of 96 lakh shares, with no fresh issue component.

Investment and Allocation

Retail investors needed to invest a minimum amount of ₹14,960, corresponding to a lot size of 110 shares. The share allocation was divided as follows:

  • Non-Institutional Investors (NII): 15%
  • Retail Investors: 35%
  • Qualified Institutional Buyers (QIB): 50%

Key Players

Pantomath Capital Advisors served as the book-running lead manager, and Kfin Technologies Limited acted as the registrar for the IPO.

Company Overview

Incorporated in 2008, Kronox Lab Sciences Limited specializes in manufacturing high-purity specialty fine chemicals used across various industries, including pharmaceuticals, biotech, nutraceuticals, agrochemicals, personal care, and more. The company offers over 185 products such as phosphate, sulphate, acetate, chloride, citrate, nitrates, nitrites, carbonate, EDTA derivatives, hydroxide, succinate, and gluconate. Kronox Lab Sciences caters to both domestic and international markets, supplying to over 20 countries.

Financial Performance

The company’s revenue increased by 16.99% and its profit after tax (PAT) rose by 21.94% between the financial years ending March 31, 2022, and March 31, 2023.

Industry Peers

Kronox Lab Sciences competes with other firms in the specialty chemicals sector, including:

  • Tanfac Industries Ltd: P/E of 39.15
  • Neogen Chemicals Ltd: P/E of 77.55
  • Sigachi Industries Ltd: P/E of 46.64
  • Tatva Chintan Pharma Chem Ltd: P/E of 57.57
  • DMCC Speciality Chemical Ltd: P/E of 116.57

The successful IPO debut of Kronox Lab Sciences reflects strong investor interest and confidence in the company’s growth prospects and market position within the specialty chemicals sector.

Latest Q4 Results

Currency Market Analysis

Disclaimer:

CurrencyVeda provides this news article for informational purposes only. We do not offer investment advice or recommendations. Before making any investment decisions, please conduct thorough research, consult with financial experts, and carefully consider your financial situation, risk tolerance, and investment goals. Investing in the stock market carries risks, and it’s essential to make informed choices based on your individual circumstances. CurrencyVeda is not liable for any actions taken based on the information provided in this article.